The obesity-induced adipokine sST2 exacerbates adipose T<sub>reg</sub> and ILC2 depletion and promotes insulin resistance.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32426492.
- Also identified by DOI 10.1126/sciadv.aay6191 and PMC identifier 7220368.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Depletion of fat-resident regulatory T cells (T<sub>regs</sub>) and group 2 innate lymphoid cells (ILC2s) has been causally linked to obesity-associated insulin resistance. However, the molecular nature of the pathogenic signals suppress adipose T<sub>regs</sub> and ILC2s in obesity remains unknown. Here, we identified the soluble isoform of interleukin (IL)-33 receptor ST2 (sST2) as an obesity-induced adipokine that attenuates IL-33 signaling and disrupts T<sub>reg</sub>/ILC2 homeostasis in adipose tissue, thereby exacerbates obesity-associated insulin resistance in mice. We demonstrated sST2 is a target of TNFα signaling in adipocytes that is countered by Zbtb7b. Fat-specific ablation of Zbtb7b augments adipose sST2 gene expression, leading to diminished fat-resident T<sub>regs</sub>/ILC2s, more pronounced adipose tissue inflammation and fibrosis, and impaired glucose homeostasis in mice. Mechanistically, Zbtb7b suppresses NF-κB activation in response to TNFα through destabilizing IκBα. These findings uncover an adipokine-immune signaling pathway that is engaged in obesity to drive the pathological changes of the immunometabolic landscape.
Medical subject headings
- Insulin Resistance